Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT111 and cemiplimab in anti-PD-1-refractory melanoma
NCT04526899Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- May 2021
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 7
01
Overview
A Phase 2 trial of enomimeran in melanoma, sponsored by BioNTech SE. Started May 2021; status: completed.
02
Drugs
enomimeran
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04526899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526899.